Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Related Citations for PubMed (Select 24376158)

1.

Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.

Chen K, Man K, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q.

Liver Transpl. 2014 Mar;20(3):261-9. doi: 10.1002/lt.23806. Epub 2014 Jan 27. Review.

2.

Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.

Welker MW, Bechstein WO, Zeuzem S, Trojan J.

Transpl Int. 2013 Feb;26(2):109-18. doi: 10.1111/j.1432-2277.2012.01562.x. Epub 2012 Sep 21. Review.

PMID:
22994652
3.

Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence.

Schnitzbauer AA, Schlitt HJ, Geissler EK.

Transplantation. 2011 Jun 15;91(11):1173-6. doi: 10.1097/TP.0b013e318215e72b. Review.

PMID:
21427632
4.

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.

Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK.

BMC Cancer. 2010 May 11;10:190. doi: 10.1186/1471-2407-10-190.

5.

Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.

Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-Álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK.

J Hepatol. 2013 Dec;59(6):1193-9. doi: 10.1016/j.jhep.2013.07.012. Epub 2013 Jul 16.

PMID:
23867318
6.

Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?

Fujiki M, Aucejo F, Kim R.

Clin Transplant. 2013 Mar-Apr;27(2):169-77. doi: 10.1111/ctr.12042. Epub 2012 Dec 6. Review.

PMID:
23216662
7.

Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.

Sotiropoulos GC, Nowak KW, Fouzas I, Vernadakis S, Kykalos S, Klein CG, Paul A.

Transplant Proc. 2012 Nov;44(9):2754-6. doi: 10.1016/j.transproceed.2012.09.022.

PMID:
23146514
8.

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.

Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Sun J, Xiao YS, He YF, Wang YQ, Tang ZY.

World J Gastroenterol. 2006 May 21;12(19):3114-8.

9.

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B.

Liver Transpl. 2012 Jan;18(1):45-52. doi: 10.1002/lt.22434.

10.

Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence.

Vivarelli M, Risaliti A.

World J Gastroenterol. 2011 Nov 21;17(43):4741-6. doi: 10.3748/wjg.v17.i43.4741.

11.

Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.

Matsuda Y, Ichida T, Fukumoto M.

Med Mol Morphol. 2011 Sep;44(3):117-24. doi: 10.1007/s00795-011-0547-2. Epub 2011 Sep 16. Review.

PMID:
21922382
12.

Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.

Alsina AE, Makris A, Nenos V, Sucre E, Arrobas J, Franco E, Kemmer N.

Am Surg. 2014 Jul;80(7):680-4.

PMID:
24987900
13.

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I.

Liver Transpl. 2008 May;14(5):633-8. doi: 10.1002/lt.21420.

14.

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.

Wang Y, Speeg KV, Washburn WK, Halff G.

World J Gastroenterol. 2010 Nov 21;16(43):5518-22.

15.

Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.

Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS.

Eur J Gastroenterol Hepatol. 2013 Feb;25(2):180-6. doi: 10.1097/MEG.0b013e328359e550. Review.

PMID:
23044808
16.

[Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].

Hu AB, He XS, Tai Q, Zhu XF, Ma Y, Wang DP, Wang GD, Wu LW, Ju WQ, Huang JF.

Zhonghua Yi Xue Za Zhi. 2012 May 15;92(18):1264-7. Chinese.

PMID:
22883065
17.

Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.

Rowe IA.

Hepatology. 2010 Sep;52(3):1171-2. doi: 10.1002/hep.23702. No abstract available.

PMID:
20812364
18.

Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.

Sposito C, Mariani L, Germini A, Flores Reyes M, Bongini M, Grossi G, Bhoori S, Mazzaferro V.

J Hepatol. 2013 Jul;59(1):59-66. doi: 10.1016/j.jhep.2013.02.026. Epub 2013 Mar 14.

PMID:
23500153
19.

Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.

Pfeiffenberger J, Koschny R, Hoffmann K, Mehrabi A, Schmitz A, Radeleff B, Stremmel W, Schemmer P, Ganten TM.

Langenbecks Arch Surg. 2013 Dec;398(8):1123-8. doi: 10.1007/s00423-013-1114-1. Epub 2013 Oct 4.

PMID:
24091908
20.

Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.

Jia N, Liou I, Halldorson J, Carithers R, Perkins J, Reyes J, Yeh M, Stohr E, Rao S, Lin EH.

Anticancer Res. 2013 Jun;33(6):2797-800.

PMID:
23749944
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk